

Wenyu Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3530955/publications.pdf>

Version: 2024-02-01

13
papers

94
citations

1684188

5
h-index

1474206

9
g-index

14
all docs

14
docs citations

14
times ranked

135
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between urinary environmental phenols and the prevalence of cardiovascular diseases in US adults. <i>Environmental Science and Pollution Research</i> , 2022, 29, 42947-42954.	5.3	8
2	Block of Proliferation 1 Promotes Proliferation, Invasion and Epithelial Mesenchymal Transformation in Gastric Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-10.	4.0	6
3	Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature. <i>Journal of Translational Medicine</i> , 2022, 20, 186.	4.4	22
4	Promising Response to Lenalidomide-Combination Therapy in a Discordant Lymphoma Consisting of EBV-Positive Diffuse Large B-Cell Lymphoma and Angioimmunoblastic T-Cell Lymphoma: A Case Report. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2489-2495.	2.0	3
5	Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review. <i>Cancer Biology and Therapy</i> , 2021, , 1-7.	3.4	2
6	<p>lbrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4877-4892.	2.0	19
7	lbrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma. <i>Cancer Biology and Therapy</i> , 2020, 21, 303-308.	3.4	1
8	The $\hat{\beta}$ -secretase inhibitor GSH interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis. <i>Cellular Signalling</i> , 2019, 59, 76-84.	3.6	2
9	Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review. <i>Cancer Biology and Therapy</i> , 2018, 19, 549-553.	3.4	6
10	LAMP1 Overexpression Predicts for Poor Prognosis in Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 749-754.	0.4	4
11	High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2017, 96, 1485-1491.	1.8	11
12	TrkA is a binding partner of $\langle \text{sc} \rangle \text{NPM} \langle \text{sc} \rangle \hat{\text{a}} \langle \text{sc} \rangle \text{ALK} \langle \text{sc} \rangle$ that promotes the survival of $\langle \text{sc} \rangle \text{ALK} \langle \text{sc} \rangle \langle \text{sup} \rangle + \langle \text{sc} \rangle$ Tâ€cell lymphoma. <i>Molecular Oncology</i> , 2017, 11, 1189-1207.	4.6	6
13	Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms. <i>Oncotarget</i> , 2015, 6, 14953-14969.	1.8	4